Hypertension is a major risk factor for cardiovascular disease. The somatic isoform of angiotensin converting enzyme (sACE) is a two-domain type-I integral membrane protein which plays a key role in blood pressure regulation. It is thus an important anti-hypertensive drug target and ACE inhibitors are widely prescribed.
However, their use is associated with side-effects and the mechanism of chronic sACE inhibition is unclear. While acute sACE inhibition decreases blood pressure by lowering production of the vasoconstrictor, angiotensin II (AngII), prolonged treatment restores AngII levels to baseline, yet the cardioprotective benefits remain.
Inhibitor binding is associated with inter-domain cooperativity and increases sACE homo-dimerization. Dimerization could explain the long-term beneficial effects of sACE inhibition since it initiates intra-cellular signaling, and likely regulates proteolytic release (shedding) of sACE from the cell membrane. Since the crystal structures have only been determined of the truncated, minimally glycosylated domains, it is unclear how cooperativity and dimerization occur. These mechanisms are important to uncover since it may provide a novel means for targeting sACE independent of its catalytic activity, thus limiting its side effects.

